ClinicalTrials.gg
CompletedNCT03141177CheckMate 9ERUpdated Aug 24, 2026Results posted

A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

A Phase 3 interventional study of Nivolumab and Cabozantinib in Renal Cell Carcinoma, sponsored by Bristol-Myers Squibb. Completed at 135 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-24.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
701
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 63 studies testing nivolumab in Carcinoma, Renal Cell — 9 open to participants now, 23 under way, 3 of them phase 3. Nivolumab · Carcinoma, Renal Cell.

Enrollment
9th of 63
701 · median 54
Started
2017
with 12 others
Phase 3
8 of 63
1 open now
Registered
31st of 63
by date
Lead sponsor
14 of 63
Bristol-Myers Squibb

Among the 63 studies testing nivolumab in Carcinoma, Renal Cell, this one is the 9th largest by enrollment, is one of 13 that started in 2017, is one of 8 in phase 3, and was the 31st registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

9 of the 63 studies testing nivolumab in Carcinoma, Renal Cell are open now, in 7 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Carcinoma, Renal Cell studies recruiting now, 254 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 20 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing nivolumab in Carcinoma, Renal Cell, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether Nivolumab Combined with Cabozantinib is safe and effective compared to Sunitinib in previously untreated advanced or metastatic renal cell carcinoma

03

Conditions studied

  • Renal Cell Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Histological confirmation of RCC with a clear-cell component, including participants who may also have sarcomatoid features
  • Advanced (not amenable to curative surgery or radiation therapy) or (AJCC Stage IV) RCC
  • No prior systemic therapy for RCC with the following exception:

    i) One prior or neoadjuvant therapy for completely resectable RCC if such therapy did not include an agent that targets VEGF or VEGF receptors and if recurrence occurred at least 6 months after the last dose of adjuvant or neoadjuvant therapy

Exclusion criteria

Exclusion Criteria:

  • Any active
  • Any active, known or suspected disease
  • Any condition requiring systemic treatment with either (> 10 mg daily prednisone equivalent) or other medications within 14 days of randomization
  • Participants who have received a live/attenuated vaccine within 30 days of first treatment

Other protocol defined inclusion/exclusion criteria could apply

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
701 participants (actual)

Study arms

  • Experimental
    Doublet

    Nivolumab and Cabozantinib

    Biological: Nivolumab · Drug: Cabozantinib

  • Active comparator
    Monotherapy

    Sunitinib

    Drug: Sunitinib

  • Experimental
    Triplet

    Nivolumab, Ipilimumab, Cabozantinib \*Enrollment to the triplet arm was discontinued by protocol amendment

    Biological: Ipilimumab

Interventions

  • BiologicalNivolumab

    Specified dose on specified day

    Also known as: Opdivo, BMS-936558

  • Specified dose on specified days

    Also known as: Cabometyx

  • Specified dose on specified days.

    Also known as: Sutent

  • BiologicalIpilimumab

    Specified dose on specified days

    Also known as: Yervoy, BMS-734016

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    PFS is defined as the time from date of randomization to the first documented tumor progression date or death due to any cause, whichever occurs first based on BICR assessment using RECIST v1.1. Participants who die without a reported progression will be considered to have progressed on the date of their death. Participants who did not progress or die will be censored on the date of their last evaluable tumor assessment on or prior to initiation of subsequent anti-cancer therapy. Progressive disease (PD); 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study

    Time frame: From randomization date to date of first documented tumor progression or death, whichever occurs first (Up to 31 months)

Secondary outcomes

  1. Overall Survival (OS)

    Overall Survival is defined as the time between the date of randomization and the date of death due to any cause. For participants that are alive, their survival time will be censored at the date of last contact date (or "last known alive date").

    Time frame: From randomization date to death date (Up to 31 months)

  2. Objective Response Rate (ORR)

    Objective Response Rate (ORR) is defined as the percentage of randomized participants who achieve a best response of confirmed complete response (CR) or confirmed partial response (PR) based on BICR assessments (using RECIST v1.1 criteria) divided by the number of all randomized participants. Complete response (CR): Disappearance of all target lesions. Partial response (PR): 30% decrease in the sum of diameters of target lesions.

    Time frame: Up to 31 Months

  3. Number of Participants Experiencing Adverse Events (AEs)

    Number of participants experiencing various types of any grade adverse events (AEs) during the specified time frame.

    Time frame: From first dose to 100 days following last dose (Up to 32 Months)

  4. Number of Participants Experiencing Serious Adverse Events (SAEs)

    Number of participants experiencing various types of any grade serious adverse events (SAEs) during the specified time frame.

    Time frame: From first to dose to 100 days following last dose (Up to 32 months)

  5. Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation

    Number of participants experiencing various types of any grade adverse events (AEs) leading to discontinuation during the specified time frame.

    Time frame: From first dose to 30 days following last dose (Up to 30 months)

  6. Number of Deaths

    Number of deaths due to any cause during the specified time frame.

    Time frame: From first dose to (up to 31 months) following first dose

  7. Number of Participants With Laboratory Abnormalities

    Number of participants experiencing laboratory abnormalities in hematology, serum chemistry and electrolytes with grade 3 or higher during the specified time frame.

    Time frame: From first dose to 30 days following last dose (Up to 30 Months)

  8. Number of Participants With Laboratory Values Grade Shifting From Baseline

    Number of participants experiencing worsening shift from baseline in any grade and grade 3-4 of laboratory values during the specified time frame.

    Time frame: From first dose to 30 days following last dose (Up to 30 Months)

07

Results

Posted Apr 26, 2022

Participant flow

Participant flow — Overall Study
MilestoneTreatment ATreatment BTreatment C
Started32350328
Treated32050320
Completed24234210
Not completed8116118
Withdrew: Death621384
Withdrew: Participant withdrew consent9213
Withdrew: Not reported101
Withdrew: Lost to follow-up211
Withdrew: Other reasons4011
Withdrew: Participants did not start treatment period308

Outcome measures

PrimaryProgression Free Survival (PFS)

PFS is defined as the time from date of randomization to the first documented tumor progression date or death due to any cause, whichever occurs first based on BICR assessment using RECIST v1.1. Participants who die without a reported progression will be considered to have progressed on the date of their death. Participants who did not progress or die will be censored on the date of their last evaluable tumor assessment on or prior to initiation of subsequent anti-cancer therapy. Progressive disease (PD); 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study

Time frame:
From randomization date to date of first documented tumor progression or death, whichever occurs first (Up to 31 months)
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsTreatment ATreatment C
Progression Free Survival (PFS)16.59 (12.45 to 24.94)8.31 (6.97 to 9.69)
Statistical analysis
  • Treatment A vs Treatment C · Stratified Log-Rank · p = <0.0001 · Hazard ratio (hr): 0.51 · 95% CI 0.41 to 0.64
SecondaryOverall Survival (OS)

Overall Survival is defined as the time between the date of randomization and the date of death due to any cause. For participants that are alive, their survival time will be censored at the date of last contact date (or "last known alive date").

Time frame:
From randomization date to death date (Up to 31 months)
Reported as:
Median · Months
Overall Survival (OS)
MonthsTreatment ATreatment C
Overall Survival (OS)NA (NA to NA)NA (22.6 to NA)
Statistical analysis
  • Treatment A vs Treatment C · Stratified Log-Rank · p = 0.0010 · Hazard ratio (hr): 0.60 · 98.89% CI 0.40 to 0.89
SecondaryObjective Response Rate (ORR)

Objective Response Rate (ORR) is defined as the percentage of randomized participants who achieve a best response of confirmed complete response (CR) or confirmed partial response (PR) based on BICR assessments (using RECIST v1.1 criteria) divided by the number of all randomized participants. Complete response (CR): Disappearance of all target lesions. Partial response (PR): 30% decrease in the sum of diameters of target lesions.

Time frame:
Up to 31 Months
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR)
Percentage of ParticipantsTreatment ATreatment BTreatment C
Objective Response Rate (ORR)55.7 (50.1 to 61.2)44.0 (30.0 to 58.7)27.1 (22.4 to 32.3)
Statistical analysis
  • Treatment A vs Treatment C · Stratified Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 3.52 · 95% CI 2.51 to 4.95
  • Treatment A vs Treatment C · Difference of objective response rates: 28.6 · 95% CI 21.7 to 35.6Strata adjusted difference in objective response rate (Nivolumab+Cabozantinib - Sunitinib) based on DerSimonian and Laird.
SecondaryNumber of Participants Experiencing Adverse Events (AEs)

Number of participants experiencing various types of any grade adverse events (AEs) during the specified time frame.

Time frame:
From first dose to 100 days following last dose (Up to 32 Months)
Reported as:
Count of participants · Participants
Number of Participants Experiencing Adverse Events (AEs)
ParticipantsTreatment ATreatment BTreatment C
Number of Participants Experiencing Adverse Events (AEs)31950317
SecondaryNumber of Participants Experiencing Serious Adverse Events (SAEs)

Number of participants experiencing various types of any grade serious adverse events (SAEs) during the specified time frame.

Time frame:
From first to dose to 100 days following last dose (Up to 32 months)
Reported as:
Count of participants · Participants
Number of Participants Experiencing Serious Adverse Events (SAEs)
ParticipantsTreatment ATreatment BTreatment C
Number of Participants Experiencing Serious Adverse Events (SAEs)16028144
SecondaryNumber of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation

Number of participants experiencing various types of any grade adverse events (AEs) leading to discontinuation during the specified time frame.

Time frame:
From first dose to 30 days following last dose (Up to 30 months)
Reported as:
Count of participants · Participants
Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation
ParticipantsTreatment ATreatment BTreatment C
Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation631554
SecondaryNumber of Deaths

Number of deaths due to any cause during the specified time frame.

Time frame:
From first dose to (up to 31 months) following first dose
Reported as:
Count of participants · Participants
Number of Deaths
ParticipantsTreatment ATreatment BTreatment C
Number of Deaths671499
SecondaryNumber of Participants With Laboratory Abnormalities

Number of participants experiencing laboratory abnormalities in hematology, serum chemistry and electrolytes with grade 3 or higher during the specified time frame.

Time frame:
From first dose to 30 days following last dose (Up to 30 Months)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities
ParticipantsTreatment ATreatment BTreatment C
Hemoglobin: Any grade23535256
Hemoglobin: Grade 3-49515
Platelet Count: Any grade13727216
Platelet Count: Grade 3-41030
Leukocytes: Any grade12126207
Leukocytes: Grade 3-41016
Lymphocytes: Any grade10722118
Lymphocytes: Grade 3-416424
Neutrophil: Any grade11522209
Neutrophil: Grade 3-410236
Alkaline Phosphatase: Any grade19435167
Alkaline Phosphatase: Grade 3-41266
Aspartate Aminotransferase (AST): Any grade26043235
Aspartate Aminotransferase (AST): Grade 3-425198
Alanine Aminotransferase (ALT): Any grade26846133
Alanine Aminotransferase (ALT): Grade 3-4312411
Bilirubin: Any grade571772
Bilirubin: Grade 3-4333
Creatinine: Any grade22134211
Creatinine: Grade 3-4402
Amylase: Any grade482841
Amylase: Grade 3-4301017
Lipase: Any grade362742
Lipase: Grade 3-4462041
Hypernatremia: Any grade33724
Hypernatremia: Grade 3-4000
Hyponatremia: Any grade16031140
Hyponatremia: Grade 3-436941
Hyperkalemia: Any grade13627100
Hyperkalemia: Grade 3-41623
Hypokalemia: Any grade64837
Hypokalemia: Grade 3-41106
Hypercalcemia: Any grade40958
Hypercalcemia: Grade 3-4104
Hypocalcemia: Any grade1742577
Hypocalcemia: Grade 3-4622
Hypermagnesemia: Any grade42929
Hypermagnesemia: Grade 3-41247
Hypomagnesemia: Any grade1551890
Hypomagnesemia: Grade 3-4411
Hyperphosphatemia: Any grade000
Hyperphosphatemia: Grade 3-4000
Hypophosphatemia: Any grade22634154
Hypophosphatemia: Grade 3-4881231
Hyperglycemia: Any grade13529139
Hyperglycemia: Grade 3-4824
Hypoglycemia: Any grade721041
Hypoglycemia: Grade 3-4211
SecondaryNumber of Participants With Laboratory Values Grade Shifting From Baseline

Number of participants experiencing worsening shift from baseline in any grade and grade 3-4 of laboratory values during the specified time frame.

Time frame:
From first dose to 30 days following last dose (Up to 30 Months)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Values Grade Shifting From Baseline
ParticipantsTreatment ATreatment BTreatment C
Hemoglobin: Any grade11723190
Hemoglobin: Grade 3-48515
Platelet Count: Any grade12924216
Platelet Count: Grade 3-42030
Leukocytes: Any grade11626206
Leukocytes: Grade 3-41016
Lymphocytes: Any grade9520102
Lymphocytes: Grade 3-415423
Neutrophil: Any grade11222209
Neutrophil: Grade 3-410236
Alkaline Phosphatase: Any grade13131115
Alkaline Phosphatase: Grade 3-4965
Aspartate Aminotransferase (AST): Any grade24542177
Aspartate Aminotransferase (AST): Grade 3-425198
Alanine Aminotransferase (ALT): Any grade24943121
Alanine Aminotransferase (ALT) Grade 3-4312411
Bilirubin: Any grade551768
Bilirubin: Grade 3-4333
Creatinine: Any grade12322132
Creatinine: Grade 3-4402
Amylase: Any grade1172677
Amylase: Grade 3-4281016
Lipase: Any grade12727114
Lipase: Grade 3-4422040
Hypernatremia: Any grade33724
Hypernatremia: Grade 3-4000
Hyponatremia: Any grade13630111
Hyponatremia: Grade 3-434837
Hyperkalemia: Any grade1112582
Hyperkalemia: Grade 3-41523
Hypokalemia: Any grade61835
Hypokalemia: Grade 3-41005
Hypercalcemia: Any grade30746
Hypercalcemia: Grade 3-4103
Hypocalcemia: Any grade1702573
Hypocalcemia: Grade 3-4622
Hypermagnesemia: Any grade38926
Hypermagnesemia: Grade 3-41247
Hypomagnesemia: Any grade1461677
Hypomagnesemia: Grade 3-4411
Hyperphosphatemia: Any grade000
Hyperphosphatemia: Grade 3-4000
Hypophosphatemia: Any grade21133147
Hypophosphatemia: Grade 3-4851231
Hyperglycemia: Any grade741776
Hyperglycemia: Grade 3-4623
Hypoglycemia: Any grade67937
Hypoglycemia: Grade 3-4211

Adverse events

Collected over All cause mortality: From first visit to up to 31 months following first visit SAEs and AEs: From first dose to 100 days following last dose (up to 32 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A67/320 (20.9%)160/320 (50%)316/320 (98.8%)
Treatment B14/50 (28%)28/50 (56%)48/50 (96%)
Treatment C99/320 (30.9%)144/320 (45%)306/320 (95.6%)
Most frequent serious events
Showing 10 of 259
Most frequent serious events
EventTreatment ATreatment BTreatment C
PneumoniaInfections and infestations9/3204/508/320
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)24/3204/5023/320
DiarrhoeaGastrointestinal disorders15/3200/500/320
Adrenal insufficiencyEndocrine disorders6/3202/500/320
HepatitisHepatobiliary disorders2/3202/500/320
SyncopeNervous system disorders2/3202/501/320
AnaemiaBlood and lymphatic system disorders2/3201/5011/320
Pleural effusionRespiratory, thoracic and mediastinal disorders2/3200/509/320
PneumonitisRespiratory, thoracic and mediastinal disorders9/3200/501/320
Pulmonary embolismRespiratory, thoracic and mediastinal disorders9/3200/503/320
Most frequent other events
Showing 10 of 94
Most frequent other events
EventTreatment ATreatment BTreatment C
DiarrhoeaGastrointestinal disorders202/32028/50151/320
Alanine aminotransferase increasedInvestigations90/32021/5028/320
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders128/32020/50130/320
FatigueGeneral disorders102/32019/50112/320
HypertensionVascular disorders112/32018/50121/320
HypothyroidismEndocrine disorders109/32015/5095/320
Aspartate aminotransferase increasedInvestigations82/32016/5036/320
NauseaGastrointestinal disorders86/32015/5099/320
Decreased appetiteMetabolism and nutrition disorders92/32015/5066/320
RashSkin and subcutaneous tissue disorders69/32015/5026/320

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Treatment ATreatment BTreatment CTotal
Mean61.4 ± 10.260.3 ± 9.560.4 ± 10.660.9 ± 10.4
Sex: Female, Male
Sex: Female, Male(Participants)Treatment ATreatment BTreatment CTotal
Female741696186
Male24934232515
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment ATreatment BTreatment CTotal
Hispanic or Latino38133990
Not Hispanic or Latino14919151319
Unknown or Not Reported13618138292
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment ATreatment BTreatment CTotal
American Indian or Alaska Native3025
Asian2602551
Native Hawaiian or Other Pacific Islander0000
Black or African American1045
White26743266576
More than one race0000
Unknown or Not Reported2673164
08

Study locations

135 sites
  • Local Institution - 0077
    Daphne, Alabama 36526, United States
  • Local Institution - 0044
    Goodyear, Arizona 85338, United States
  • Local Institution - 0132
    Tucson, Arizona 85724-5024, United States
  • Local Institution - 0133
    Bakersfield, California 93309, United States
  • Local Institution - 0093
    Los Angeles, California 90404, United States
  • Local Institution - 0090
    Redondo Beach, California 90277, United States
  • Local Institution - 0088
    San Luis Obispo, California 93401, United States
  • Central Coast Medical Oncology Corporation
    Santa Maria, California 93454, United States
  • Local Institution - 0103
    Aurora, Colorado 80045, United States
  • Local Institution - 0127
    Athens, Georgia 30607, United States
  • Local Institution - 0086
    Newnan, Georgia 30265, United States
  • Local Institution - 0036
    Chicago, Illinois 60612, United States
  • Local Institution - 0042
    Zion, Illinois 60099, United States
  • Local Institution - 0091
    Fort Wayne, Indiana 46804, United States
  • Local Institution - 0087
    Wichita, Kansas 67214, United States
  • Local Institution - 0113
    Boston, Massachusetts 02114, United States
  • Local Institution - 0037
    Boston, Massachusetts 02215, United States
  • Local Institution - 0106
    Kansas City, Missouri 64132, United States
  • Local Institution - 0035
    St Louis, Missouri 63110, United States
  • Local Institution - 0102
    Las Vegas, Nevada 89169, United States
  • Local Institution - 0040
    Buffalo, New York 14263, United States
  • Local Institution - 0017
    New York, New York 10065, United States
  • Local Institution - 0067
    Portland, Oregon 97239, United States
  • Local Institution - 0135
    Allentown, Pennsylvania 18103, United States
  • Local Institution - 0105
    Nashville, Tennessee 37203, United States
  • Local Institution - 0080
    Austin, Texas 78705, United States
  • Local Institution - 0075
    Dallas, Texas 75246, United States
  • Local Institution - 0068
    Houston, Texas 77030, United States
  • Local Institution - 0078
    Sherman, Texas 75090, United States
  • Local Institution - 0131
    Norfolk, Virginia 23502, United States
  • Local Institution - 0046
    CABA, Buenos Aires C1120AAT, Argentina
  • Local Institution - 0048
    Ciudad Autonoma de Buenos Aire, Buenos Aires 1181, Argentina
  • Local Institution - 0114
    Viedma, Río Negro Province 8500, Argentina
  • Local Institution - 0138
    CABA, 1426, Argentina
  • Local Institution - 0050
    Córdoba, 5000, Argentina
  • Local Institution - 0049
    Córdoba, X5004FHP, Argentina
  • Local Institution - 0047
    San Miguel de Tucumán, 4000, Argentina
  • Local Institution - 0002
    North Ryde, New South Wales 0, Australia
  • Local Institution - 0008
    Sydney, New South Wales 2010, Australia
  • Local Institution - 0009
    Sydney, New South Wales 2139, Australia
  • Local Institution - 0073
    Westmead, New South Wales 2145, Australia
  • Local Institution - 0006
    Herston, Queensland 4006, Australia
  • Local Institution - 0001
    Southport, Queensland 4215, Australia
  • Local Institution - 0004
    Elizabeth Vale, South Australia 5112, Australia
  • Local Institution - 0005
    Malvern, Victoria 3144, Australia
  • Local Institution - 0007
    Doubleview, Western Australia 6018, Australia
  • Local Institution - 0129
    South Brisbane, 4101, Australia
  • Local Institution - 0057
    Belo Horizonte, Minas Gerais 30130-090, Brazil
  • Local Institution - 0119
    Ijuí, Rio Grande do Sul 98700-000, Brazil
  • Local Institution - 0056
    Porto Alegre, Rio Grande do Sul 90610-000, Brazil
  • Local Institution - 0060
    Porto Alegre, Rio Grande do Sul 91350-200, Brazil
  • Local Institution - 0058
    Barretos, São Paulo 14784-400, Brazil
  • Local Institution - 0066
    Rio de Janeiro, 20231-050, Brazil
  • Local Institution - 0074
    São Paulo, 01323-020, Brazil
  • Local Institution - 0061
    São Paulo, 05651901, Brazil
  • Local Institution - 0045
    Santiago, Santiago Metropolitan 8420383, Chile
  • Local Institution - 0034
    Hradec Králové, 500 05, Czechia
  • Local Institution - 0033
    Olomouc, 779 00, Czechia
  • Local Institution - 0013
    Aachen, 52074, Germany
  • Local Institution - 0016
    Bonn, 53127, Germany
  • Local Institution - 0117
    Essen, 45136, Germany
  • Local Institution - 0023
    Jena, 07747, Germany
  • Local Institution - 0010
    München, 81675, Germany
  • Local Institution - 0014
    Nuremberg, 90419, Germany
  • Local Institution - 0011
    Tübingen, 72076, Germany
  • Local Institution - 0082
    Athens, 115 28, Greece
  • Local Institution - 0083
    Thessaloniki, 546 45, Greece
  • Local Institution - 0072
    Haifa, 3109601, Israel
  • Local Institution - 0070
    Kfar Saba, 44281, Israel
  • Local Institution - 0071
    Petah Tikva, 49414, Israel
  • Local Institution - 0069
    Ramat Gan, 52621, Israel
  • Local Institution - 0054
    Arezzo, 52100, Italy
  • Local Institution - 0052
    Milan, 20132, Italy
  • Local Institution - 0055
    Naples, 80131, Italy
  • Local Institution - 0053
    Padova, Padova, Italy
  • Local Institution - 0051
    Pavia, 27100, Italy
  • Local Institution - 0147
    Pavia, 27100, Italy
  • Local Institution - 0172
    Terni, 05100, Italy
  • Local Institution - 0148
    Akita, Akita 010-8543, Japan
  • Local Institution - 0156
    Hirosaki, Aomori 036-8563, Japan
  • Local Institution - 0164
    Sapporo, Hokkaido 0608543, Japan
  • Local Institution - 0157
    Sapporo, Hokkaido 0608648, Japan
  • Local Institution - 0168
    Kobe, Hyōgo 6500017, Japan
  • Local Institution - 0159
    Morioka, Iwate 0208505, Japan
  • Local Institution - 0171
    Yokohama, Kanagawa 236-0004, Japan
  • Local Institution - 0166
    Yokohama, Kanagawa 241-8515, Japan
  • Local Institution - 0150
    Niigata, Niigata 9518520, Japan
  • Local Institution - 0169
    Okayama, Okayama-ken 7008558, Japan
  • Local Institution - 0170
    Osaka, Osaka 5418567, Japan
  • Local Institution - 0160
    Osakasayamashi, Osaka 5898511, Japan
  • Local Institution - 0163
    Suita-shi, Osaka 565-0871, Japan
  • Local Institution - 0154
    Osaka, Osaka-shi 545-8586, Japan
  • Local Institution - 0155
    Hidaka-shi, Saitama 3501298, Japan
  • Local Institution - 0153
    Tokushima, Tokushima 7708503, Japan
  • Local Institution - 0152
    Adachi-ku, Tokyo 123-8558, Japan
  • Local Institution - 0158
    Bunkyo-ku, Tokyo 1138519, Japan
  • Local Institution - 0151
    Bunkyo-ku, Tokyo 1138603, Japan
  • Local Institution - 0173
    Minato-ku, Tokyo 105-8470, Japan
  • Local Institution - 0167
    Chiba, 260-8717, Japan
  • Local Institution - 0161
    Fukuoka, 812-8582, Japan

Showing the first 100 of 135 sites across 18 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Bergerot C, Yu S, Yang M, Martins B, Du M, Perez Torrealba J, Hall T, Samant N, Motzer RJ, Cella D. Identification of key symptoms impacting HRQOL in advanced renal cell carcinoma: nivolumab plus cabozantinib versus sunitinib in CheckMate 9ER. Oncologist. 2026 Aug 14:oyag329. doi: 10.1093/oncolo/oyag329. Online ahead of print. PubMed 42605077 ↗
  • Viray H, M Mantia C, Jegede OA, Atkins MB, Rosenblatt L, Choueiri TK, McDermott DF, Regan MM. Partitioned overall survival: comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma. J Immunother Cancer. 2026 Jan 30;14(1):e013546. doi: 10.1136/jitc-2025-013546. PubMed 41617395 ↗
  • Grimm MO, Karim E, Kapetanakis V, Lothgren M, Ogareva A, Shukla P, Truscott J, Porta C. Two-Stage Estimation of Overall Survival in the Phase 3 CheckMate 9ER Trial, Adjusting for the Impact of Subsequent Therapy. Oncol Ther. 2026 Mar;14(1):253-268. doi: 10.1007/s40487-025-00393-9. Epub 2025 Nov 15. PubMed 41239083 ↗
  • Motzer RJ, Escudier B, Burotto M, Powles T, Apolo AB, Bourlon MT, Shah AY, Porta C, Suarez C, Barrios CH, Richardet M, Gurney H, Kessler ER, Tomita Y, Bedke J, Scheffold C, Askelson M, Panzica J, Zhang J, van Kooten Losio M, Choueiri TK. Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial. Ann Oncol. 2026 Jan;37(1):33-43. doi: 10.1016/j.annonc.2025.09.006. Epub 2025 Sep 23. PubMed 40998092 ↗
  • Cella D, Motzer RJ, Suarez C, Blum SI, Ejzykowicz F, Hamilton M, Wallace JF, Simsek B, Zhang J, Ivanescu C, Choueiri TK, Apolo AB. Plain language summary of quality of life in CheckMate 9ER: Cabozantinib plus nivolumab in advanced renal cell carcinoma. Future Oncol. 2025 Jan;21(2):181-194. doi: 10.1080/14796694.2024.2415786. Epub 2024 Oct 25. PubMed 39452894 ↗
  • Powles T, Burotto M, Escudier B, Apolo AB, Bourlon MT, Shah AY, Suarez C, Porta C, Barrios CH, Richardet M, Gurney H, Kessler ER, Tomita Y, Bedke J, George S, Scheffold C, Wang P, Fedorov V, Motzer RJ, Choueiri TK. Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial. ESMO Open. 2024 May;9(5):102994. doi: 10.1016/j.esmoop.2024.102994. Epub 2024 Apr 20. PubMed 38642472 ↗
  • Petersohn S, McGregor B, Klijn SL, May JR, Ejzykowicz F, Kurt M, Dyer M, Malcolm B, Branchoux S, Nickel K, George S, Kroep S. Challenges in conducting fractional polynomial and standard parametric network meta-analyses of immune checkpoint inhibitors for first-line advanced renal cell carcinoma. J Comp Eff Res. 2023 Aug;12(8):e230004. doi: 10.57264/cer-2023-0004. Epub 2023 Jul 11. PubMed 37431849 ↗
  • Aldin A, Besiroglu B, Adams A, Monsef I, Piechotta V, Tomlinson E, Hornbach C, Dressen N, Goldkuhle M, Maisch P, Dahm P, Heidenreich A, Skoetz N. First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2023 May 4;5(5):CD013798. doi: 10.1002/14651858.CD013798.pub2. PubMed 37146227 ↗
  • Tran BD, Li J, Ly N, Faggioni R, Roskos L. Cabozantinib exposure-response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma. Cancer Chemother Pharmacol. 2023 Feb;91(2):179-189. doi: 10.1007/s00280-022-04500-9. Epub 2023 Jan 10. PubMed 36625894 ↗
  • Apolo AB, Powles T, Escudier B, Burotto M, Zhang J, Simsek B, Scheffold C, Motzer RJ, Choueiri TK. Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial. Eur J Cancer. 2022 Dec;177:63-71. doi: 10.1016/j.ejca.2022.09.020. Epub 2022 Oct 4. PubMed 36327527 ↗
  • Motzer RJ, Powles T, Burotto M, Escudier B, Bourlon MT, Shah AY, Suarez C, Hamzaj A, Porta C, Hocking CM, Kessler ER, Gurney H, Tomita Y, Bedke J, Zhang J, Simsek B, Scheffold C, Apolo AB, Choueiri TK. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncol. 2022 Jul;23(7):888-898. doi: 10.1016/S1470-2045(22)00290-X. Epub 2022 Jun 7. PubMed 35688173 ↗
  • Cella D, Motzer RJ, Suarez C, Blum SI, Ejzykowicz F, Hamilton M, Wallace JF, Simsek B, Zhang J, Ivanescu C, Apolo AB, Choueiri TK. Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial. Lancet Oncol. 2022 Feb;23(2):292-303. doi: 10.1016/S1470-2045(21)00693-8. Epub 2022 Jan 12. PubMed 35032437 ↗
  • Hamuro L, Hu Z, Passarell J, Barcomb H, Zhang J, Goldstein S, Bello A, Roy A, Zhu L. Exposure-Response Analysis to Support Nivolumab Once Every 4 Weeks Dosing in Combination with Cabozantinib in Renal Cell Carcinoma. Clin Cancer Res. 2022 Apr 14;28(8):1603-1613. doi: 10.1158/1078-0432.CCR-21-3149. PubMed 34980597 ↗
  • Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, Oyervides Juarez VM, Hsieh JJ, Basso U, Shah AY, Suarez C, Hamzaj A, Goh JC, Barrios C, Richardet M, Porta C, Kowalyszyn R, Feregrino JP, Zolnierek J, Pook D, Kessler ER, Tomita Y, Mizuno R, Bedke J, Zhang J, Maurer MA, Simsek B, Ejzykowicz F, Schwab GM, Apolo AB, Motzer RJ; CheckMate 9ER Investigators. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2021 Mar 4;384(9):829-841. doi: 10.1056/NEJMoa2026982. PubMed 33657295 ↗
  • Hofmann F, Hwang EC, Lam TB, Bex A, Yuan Y, Marconi LS, Ljungberg B. Targeted therapy for metastatic renal cell carcinoma. Cochrane Database Syst Rev. 2020 Oct 14;10(10):CD012796. doi: 10.1002/14651858.CD012796.pub2. PubMed 33058158 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2017 to primary completion in Feb 2020, 30 months.

Results were first posted in Apr 2022, 2 years 2 months after primary completion. A results delay was requested in Feb 2021.

Of 35 industry-sponsored phase 3 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 59. This study's 30 months is below that.

Counting every sponsor, half of 61 studies reached it within 56 months; a quarter within 42 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2017
First posted
May 4, 2017
StartActual
Jul 23, 2017
Primary completionActual
Feb 12, 2020
CompletionActual
Apr 1, 2026
Results delay requested
Feb 11, 2021
Results first posted
Apr 26, 2022
Last update
Aug 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03141177
Responsible party
Sponsor
First posted
May 4, 2017
Start date
Jul 23, 2017
Primary completion
Feb 12, 2020
Completion
Apr 1, 2026
Results posted
Apr 26, 2022
Last update
Aug 24, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Cabozantinib · Ipilimumab

Start the discussion